title: Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.
authors.affiliation: Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048; email: Anna.Selvaggio@cshs.org , Paul.Noble@cshs.org.
authors.forename: Anna S
authors.initials: AS
authors.lastname: Selvaggio
authors.affiliation: Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048; email: Anna.Selvaggio@cshs.org , Paul.Noble@cshs.org.
authors.forename: Paul W
authors.initials: PW
authors.lastname: Noble
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy*; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; C093844:pirfenidone
keywords: Esbriet®; idiopathic pulmonary fibrosis; interstitial lung disease; pirfenidone